RDY changes
Pick any two versions below to diff them.
- Price
- $14.73 → $14.90(+1.2%)
- Thesis
- The price of Dr. Reddy's depends on whether new products can replace the profit from generic lenalidomide in the United States. North America revenues fell 23% in Q2 fiscal 2027 and 29% in the first half, mostly because lenalidomide sales fell, and the gross margin fell to 49.4% in the first half from 55.8%. For the price to rise, three things must be true. Generic semaglutide, which was approved in 10 countries by October 23, 2026 and in Brazil on November 5, 2026, must reach patients after the company fixes the problem with the active ingredient that caused a provision of Rs.2,397 million in Q1 fiscal 2027. Biosimilars, such as rituximab in the United States, and new launches in India and emerging markets must keep growing. The USFDA removed: must close added: closed its removed: observations at added: inspection of the Bachupally formulations plant added: as Voluntary Action Indicated on November 14, 2026, and added: it must also close its observations at the API plant in Mexico without a warning letter. The Q3 fiscal 2027 report, expected in late January 2027, is the next test. If semaglutide supply stays stopped or US generic prices fall, profit can stay low for longer.
- Risks
- The profit from generic lenalidomide in the United States is going away. North America revenues were Rs.46,938 million in the first half of fiscal 2027, against Rs.66,531 million a year earlier. Semaglutide is the largest new product, and some batches failed specification because of the active ingredient. Supply must resume, and many generic makers can enter the same markets and cut prices. USFDA inspections can delay approvals. In 2026 the company received a Form 483 with four observations at FTO-3 in Bachupally and a Form 2953 with two observations at its API plant in Mexico. added: The USFDA closed the FTO-3 inspection as Voluntary Action Indicated on November 14, 2026. Russia revenues were Rs.10.1 billion in Q2 fiscal 2027, so sanctions or the rouble can change results. The company reports in rupees, so the ADS price in dollars also moves with the rupee. Generic prices in Europe fall, and nicotine replacement therapy revenues fell 6% in Q2 fiscal 2027.
- Recent events
- Nov added: 14, 2026: The USFDA classified the GMP inspection of the FTO-3 formulations plant in Bachupally, Hyderabad, which Dr. Reddy's reported on August 14, 2026, as Voluntary Action Indicated, and it closed the inspection. Nov 5, 2026: Brazil's National Health Surveillance Agency (ANVISA) gave Dr. Reddy's marketing authorization for generic semaglutide injection for adults with type 2 diabetes. Oct 28, 2026: The USFDA classified the July 2026 inspection of FTO-SEZ Process Unit-02 at Srikakulam, Andhra Pradesh, as Voluntary Action Indicated. Oct 23, 2026: Dr. Reddy's reported Q2 fiscal 2027 results. Revenues were Rs.86,708 million, down 1.5% from a year earlier and up 7.4% from Q1. EBITDA was Rs.17,828 million, or 20.6% of revenues, and profit attributable to equity holders was Rs.9,250 million. North America revenues fell 23%, mostly because of lower lenalidomide sales, while India grew 17% and Emerging Markets grew 24%. Oct 23, 2026: In Q2 fiscal 2027, Dr. Reddy's got USFDA approval for a rituximab biosimilar, launched sugammadex injection first to market in the United States and said that some batches of semaglutide failed specification because of a problem with the active ingredient. It also received a Form 483 with four observations at its FTO-3 plant in Bachupally, Hyderabad. Oct 21, 2026: The Drugs Controller General of India approved Zytorvi (toripalimab) for advanced esophageal squamous cell carcinoma, its second approved use in India.